medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2020, Number 4

<< Back Next >>

Rev Mex Urol 2020; 80 (4)

Effects of botulinum toxin on the glandular portion of the prostate: pathophysiologic bases, mechanism of action, and evidence

Piamo MA, Ferrer MD

Language: Spanish
References: 61
Page: 1-16
PDF size: 271.84 Kb.


ABSTRACT

Botulinum toxin is a potent neurotoxin that inhibits neuromuscular junctions by blocking the release of acetylcholine and desensitizes sensory nerves. In the prostate, it effects are not limited to the neuromuscular junction, but also affect the neuroglandular junction, placing the intraprostatic injection of botulinum toxin among the new treatment options for benign prostatic hyperplasia. Considering its potential as an effective therapy in prostate conditions, while at the same time its mechanisms of action are not clear, the aim of the present review was to organize the current evidence and describe the currently known pathophysiologic bases and mechanism of action involved to encourage new research. After conducting the review of the evidence, it was concluded that botulinum toxin could induce involution of the prostate in rats, dogs, and humans, without causing local inflammation or significant systemic side effects, suggesting the possibility of its use in benign or malignant prostate lesions.


REFERENCES

  1. Montecucco C, Molgó J. Botulinal neurotoxins: revival of an old killer. Current Opinion in Pharmacology. 2005 Jun;5(3):274–9. doi: https://doi.org/10.1016/j.coph.2004.12.006

  2. Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786- 1862) and the ‘sausage poison’. Neurology. 1999 Nov 1;53(8):1850–1850. doi: https://doi. org/10.1212/wnl.53.8.1850

  3. Oates JA, Wood AJJ, Jankovic J, Brin MF. Therapeutic Uses of Botulinum Toxin. N Engl J Med. 1991 Apr 25;324(17):1186–94. doi: https:// doi.org/10.1056/nejm199104253241707

  4. Lim SK, Quek PLC. Intraprostatic and Bladder-Neck Injection of Botulinum A Toxin in Treatment of Males with Bladder-Neck Dyssynergia: A Pilot Study. European Urology. 2008 Mar 1;53(3):620–7. doi: https://doi. org/10.1016/j.eururo.2007.10.001

  5. Chung E. Botulinum toxin in urology: a review of clinical potential in the treatment of urologic and sexual conditions. Expert Opin Biol Ther. 2015 Jan;15(1):95–102. doi: https://doi.org/10. 1517/14712598.2015.974543

  6. Doggweiler R, Zermann D-H, Ishigooka M, Schmidt RA. Botox-induced prostatic involution. The Prostate. 1998;37(1):44–50. doi: https://doi.org/10.1002/(sici)1097-0045(19980915) 37: 1 % 3 C 44::aid-pros7%3E3.0.co;2-8

  7. Chuang Y-C, Huang C-C, Kang H-Y, Chiang P-H, Demiguel F, Yoshimura N, et al. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol. 2006 Mar;175(3 Pt 1):1158–63. doi: https://doi. org/10.1016/s0022-5347(05)00318-6

  8. Chuang Y-C, Tu C-H, Huang C-C, Lin H-J, Chiang P-H, Yoshimura N, et al. Intraprostatic injection of botulinum toxin type- A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol. 2006 Dec;6(1):12. doi: https://doi. org/10.1186/1471-2490-6-12

  9. Kuo H-C, Liu H-T. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scandinavian Journal of Urology and Nephrology. 2009 Jan;43(3):206–11. doi: https://doi.org/10.1080/00365590902811537

  10. Ventura S, Pennefather JN, Mitchelson F. Cholinergic innervation and function in the prostate gland. Pharmacology & Therapeutics. 2002 Apr;94(1–2):93–112. doi: https://doi. org/10.1016/s0163-7258(02)00174-2

  11. Marinese D, Patel R, Walden PD. Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice. Prostate. 2003 Feb 15;54(3):230–7. doi: https://doi. org/10.1002/pros.10170

  12. Kester RR, Mooppan UMM, Gousse AE, Alver JE, Gintautas J, Gulmi FA, et al. Pharmacological Characterization of Isolated Human Prostate. Journal of Urology. 2003 Sep;170(3):1032– 8. doi: https://doi.org/10.1097/01. ju.0000080440.74266.b1

  13. Hedlund H, Andersson K-E, Larsson B. Alpha- Adrenoceptors and Muscarinic Receptors in the Isolated Human Prostate. Journal of Urology. 1985 Dec;134(6):1291–8. doi: https://doi. org/10.1016/s0022-5347(17)47714-7

  14. Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. The Prostate. 1997;33(1):1–8. doi: https://doi.org/10.1002/ (SICI)1097-0045(19970915)33:1%3C1::AIDPROS1% 3E3.0.CO;2-P

  15. Addicks K, Bloch W, Feelisch M. Nitric oxide modulates sympathetic neurotransmission at the prejunctional level. Microsc Res Tech. 1994 Oct 1;29(2):161–8. doi: https://doi. org/10.1002/jemt.1070290214

  16. Nishiyama Y, Yokoyama T, Tomizawa K, Okamura K, Yamamoto Y, Matsui H, et al. Effects of Purified Newly Developed Botulinum Neurotoxin Type A in Rat Prostate. Urology. 2009 Aug;74(2):436–9. doi: https://doi. org/10.1016/j.urology.2009.01.047

  17. Iturralde JF. Uso actual de la toxina botulínica en enfermedades urológicas. Anuario Fundación DrJR Villavicencio. 2008;144–9.

  18. Jhang J-F, Kuo H-C. Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action. Toxins. 2016 Apr 21;8(4):120. doi: https://doi. org/10.3390/toxins8040120

  19. Lin ATL, Yang AH, Chen K-K. Effects of Botulinum Toxin A on the Contractile Function of Dog Prostate. European Urology. 2007 Aug;52(2):582–9. doi: https://doi. org/10.1016/j.eururo.2007.03.002

  20. Silva J, Pinto R, Carvallho T, Coelho A, Avelino A, Dinis P, et al. Mechanisms of Prostate Atrophy after Glandular Botulinum Neurotoxin Type A Injection: An Experimental Study in the Rat. European Urology. 2009 Jul;56(1):134–41. doi: https://doi.org/10.1016/j.eururo.2008.07.003

  21. Witte LPW, Chapple CR, de la Rosette JJMCH, Michel MC. Cholinergic Innervation and Muscarinic Receptors in the Human Prostate. European Urology. 2008 Aug;54(2):326–34. doi: https://doi.org/10.1016/j.eururo.2007.12.007

  22. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther. 1980 Jan 1;212(1):16–21.

  23. MacKenzie I, Burnstock G, Dolly JO. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience. 1982 Apr;7(4):997–1006. doi: https://doi. org/10.1016/0306-4522(82)90056-2

  24. Smith Christopher P., Franks Michael E., McNEIL BRIAN K., Ghosh Rudrani, de GROAT WILLIAM C., Chancellor Michael B., et al. Effect of Botulinum Toxin A on the Autonomic Nervous System of the Rat Lower Urinary Tract. Journal of Urology. 2003 May 1;169(5):1896– 900. doi: https://doi.org/10.1097/01. ju.0000049202.56189.54

  25. Rapp DE, Turk KW, Bales GT, Cook SP. Botulinum Toxin Type A Inhibits Calcitonin Gene-Related Peptide Release From Isolated Rat Bladder. Journal of Urology. 2006 Mar;175(3):1138–42. doi: https://doi. org/10.1016/s0022-5347(05)00322-8

  26. Kyprianou N. Doxazosin and Terazosin Suppress Prostate Growth by Inducing Apoptosis: Clinical Significance. Journal of Urology. 2003 Apr;169(4):1520–5. doi: https:// doi.org/10.1097/01.ju.0000033280.29453.72

  27. Smith CP, Chancellor MB. EMERGING ROLE OF BOTULINUM TOXIN IN THE MANAGEMENT OF VOIDING DYSFUNCTION. Journal of Urology. 2004 Jun;171(6 Part 1):2128–37. doi: https://doi.org/10.1097/01. ju.0000127725.48479.89

  28. Karsenty G, Rocha J, Chevalier S, Scarlata E, Andrieu C, Zouanat FZ, et al. Botulinum Toxin Type A Inhibits the Growth of LNCaP Human Prostate Cancer Cells In Vitro and In Vivo. Prostate. 2009 Aug 1;69(11):1143–50. doi: https://doi.org/10.1002/pros.20958

  29. Proietti S, Nardicchi V, Porena M, Giannantoni A. Botulinum Toxin Type-A Toxinactivity in Prostate Cancer Cell Lines. Urologia Journal. 2012 Apr;79(2):135–41. doi: https://doi. org/10.5301/ru.2012.9254

  30. Cell atlas - SNAP25 - The Human Protein Atlas. [accessed 2 Jun 2020] Available from: http:// www.proteinatlas.org/ENSG00000132639- SNAP25/cell/HPA001830

  31. Dasgupta P. OnabotulinumtoxinA in Benign Prostatic Hyperplasia. European Urology. 2013 Mar;63(3):504–5. doi: https://doi. org/10.1016/j.eururo.2012.10.051

  32. Park DS, Cho TW, Lee YK, Lee YT, Hong YK, Jang WK. Evaluation of Short Term Clinical Effects and Presumptive Mechanism of Botulinum Toxin Type A as a Treatment Modality of Benign Prostatic Hyperplasia. Yonsei Med J. 2006;47(5):706. doi: https://doi. org/10.3349/ymj.2006.47.5.706

  33. Marchal C, Perez JE, Herrera B, Machuca FJ, Redondo M. The use of botulinum toxin in benign prostatic hyperplasia. Neurourol Urodyn. 2012 Jan;31(1):86–92. doi: https://doi. org/10.1002/nau.21142

  34. Xu Y-P, Yu X, Ye Z-Q, Pan T-J, Wen H-D, Wang T. [Effects of intraprostatic injection of botulinum toxin A (BTX-A) on benign prostate hyperplasia]. Zhonghua Nan Ke Xue. 2010 Oct;16(10):905–10.

  35. Chuang Y-C, Yoshimura N, Huang C-C, Wu M, Chiang P-H, Chancellor MB. Intraprostatic Botulinum Toxin A Injection Inhibits Cyclooxygenase-2 Expression and Suppresses Prostatic Pain on Capsaicin Induced Prostatitis Model in Rat. Journal of Urology. 2008 Aug;180(2):742–8. doi: https://doi. org/10.1016/j.juro.2007.07.120

  36. Motheo TF, Alves AE, Mostachio GQ, Apparício M, Ribeiro AP, Souza FF de, et al. Semen parameters and seminal plasma protein and biochemical profiles of dogs with benign prostatic hyperplasia after botulinum toxin type A intraprostatic injection. Ciência Rural. 2014 Jun;44(6):1113–8. doi: http://dx.doi. org/10.1590/S0103-84782014000600026

  37. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003 Aug;62(2):259–64. doi: https://doi. org/10.1016/s0090-4295(03)00477-1

  38. Chuang Y-C, Chiang P-H, Huang C-C, Yoshimura N, Chancellor MB. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology. 2005 Oct;66(4):775–9. doi: https:// doi.org/10.1016/j.urology.2005.04.029

  39. Silva J, Silva C, Saraiva L, Silva A, Pinto R, Dinis P, et al. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol. 2008 Jan;53(1):153–9. doi: https:// doi.org/10.1016/j.eururo.2007.08.050

  40. Kuo H-C. Prostate botulinum A toxin injection— an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology. 2005 Apr;65(4):670–4. doi: https:// doi.org/10.1016/j.urology.2004.10.077

  41. Arnouk R, Suzuki Bellucci CH, Stull RB, de Bessa Junior J, Malave CA, Gomes CM. Botulinum Neurotoxin Type A for the Treatment of Benign Prostatic Hyperplasia: Randomized Study Comparing Two Doses. The Scientific World Journal. 2012;2012:1–6. doi: https://doi. org/10.1100/2012/463574

  42. Crawford ED, Hirst K, Kusek JW, Donnell RF, Kaplan SA, McVary KT, et al. Effects of 100 and 300 Units of Onabotulinum Toxin A on Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Phase II Randomized Clinical Trial. Journal of Urology. 2011 Sep;186(3):965– 70. doi: https://doi.org/10.1016/j. juro.2011.04.062

  43. Silva J, Pinto R, Carvalho T, Botelho F, Silva P, Oliveira R, et al. Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urology. 2009 Aug 15;9(1):9. doi: https://doi.org/10.1186/1471- 2490-9-9

  44. Guercini Federico, Giannantoni Antonella, Bard Robert L., Brisinda Giuseppe, Cadeddu Federica, Maria Giorgio, et al. 1387: Intraprostatic Botulin Toxin Injection in Patients with Severe Benign Prostatic Hyperplasia a Multicenter Feasibility Study. Journal of Urology. 2005 Apr 1;173(4S):376–7. doi: https://doi. org/10.1016/S0022-5347(18)35521-6

  45. Nikoobakht M, Daneshpajooh A, Ahmadi H, Namdari F, Rezaeidanesh M, Amini S, et al. Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with DysportTM. Scandinavian Journal of Urology and Nephrology. 2010 Apr;44(3):151–7. doi: https://doi.org/10.3109/00365591003649201

  46. Jasinski M, Drewa T, Tyloch J, Wolski Z. N56 Is botulinum toxin type A intraprostatic injections effective in patients with urinary retention? European Urology Supplements. 2009 Sep;8(8):587–8. doi: https://doi.org/10.1016/ s1569-9056(09)74831-6

  47. Crawford ED, Donnell R, Hirst K, Kusek JW, McVary KT, Mynderse L, et al. MIST Study Group 12-week results of a phase II trial of 100 and 300 Units Botulinum neurotocin type A (BONT-A) for the management of benign prostatic hyperplasia (BPH). J Urol. 2009;

  48. Kuo H-C, Liu H-T. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scandinavian Journal of Urology and Nephrology. 2009 Jan;43(3):206–11. doi: https://doi.org/10.1080/00365590902811537

  49. Mirkin YB, Bedredtdinova D. 997 COMPARATIVE STUDY OF EFFICIENCY AND SAFETY OF INTRAPROSTATIC INJECTIONS OF BOTULINUM TOXIN AND POLIDOCANOL IN MEN WITH BPH AND LUTS. European Urology Supplements. 2010;9(2):312–3.

  50. Mangera A, Chapple CR. Uso de la toxina botulínica en el tratamiento de los trastornos del tracto urinario inferior: Situación actual. Arch Esp Urol. 2010 Dec;63(10). [accessed 2 Jun 2020] Available from: http://scielo.isciii. es/scielo.php?script=sci_arttext&pid=S0004- 06142010001000001&lng=en&nrm=iso&tlng=en

  51. Hamidi Madani A, Enshaei A, Heidarzadeh A, Mokhtari G, Farzan A, Mohiti Asli M, et al. Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates. World J Urol. 2013 Feb;31(1):235– 9. doi: https://doi.org/10.1007/s00345-012- 0851-z

  52. Yokoyama T, Chuang Y-C, Chancellor MB. Update in the Use of Botulinum Toxin for the Treatment of Benign Prostatic Hyperplasia/ Lower Urinary Tract Symptoms. Curr Bladder Dysfunct Rep. 2013 Jun 1;8(2):174–9. doi: https://doi.org/10.1007/s11884-013-0177-8

  53. Larson Thayne R., Huidobro Christian, Acevedo Cristian, Mynderse Lance A., Larson Benjamin. 1386: Intraprostatic Injection of Botulinum Toxin in the Treatment of Symptomatic LUTS, Including Sequential Mris For Accurate Changes in Size of the Prostate. Journal of Urology. 2005 Apr 1;173(4S):376– 376. doi: https://doi.org/10.1016/s0022- 5347(18)35520-4

  54. Chuang Y-C, Chiang P-H, Yoshimura N, De Miguel F, Chancellor MB. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int. 2006 Nov;98(5):1033–7. doi: https:// doi.org/10.1111/j.1464-410x.2006.06479.x

  55. Reddy S, Chawla A, Thomas J. Botulinum toxin in high-risk BPH patients in retention. Indian Journal of Urology. 2008;24(2).

  56. Agrawal SK, Agarwal MM, Singh SK. Intraprostatic injection of botulinum toxin A: A promising treatment for patients with benign prostatic hyperplasia. Indian Journal of Urology. 2009 Jan 7;25(3):421.

  57. Mostachio GQ, Apparício M, Motheo TF, Alves AE, Vicente WRR. Intra-prostatic injection of botulinum toxin type A in treatment of dogs with spontaneous benign prostatic hyperplasia. Animal Reproduction Science. 2012 Aug;133(3– 4):224–8. doi: https://doi.org/10.1016/j. anireprosci.2012.06.024

  58. Marberger M, Chartier-Kastler E, Egerdie B, Lee K-S, Grosse J, Bugarin D, et al. A Randomized Double-blind Placebo-controlled Phase 2 Doseranging Study of OnabotulinumtoxinA in Men with Benign Prostatic Hyperplasia. European Urology. 2013 Mar;63(3):496–503. doi: https:// doi.org/10.1016/j.eururo.2012.10.005

  59. Ding X, Chen H, Wang W, Wang H, Huang L. The effect of botulinum toxin type A injection with ankle-foot orthosis on patients with poststroke lower limb spasticity. Chinese Journal of Physical Medicine and Rehabilitation. 2014;36(5):349–52.

  60. Sacco E, Bientinesi R, Marangi F, Totaro A, D’Addessi A, Racioppi M, et al. Patientreported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study: PROs IN MEN WITH LUTS TREATED WITH INTRAPROSTATIC BTX-A. BJU International. 2012 Dec;110(11c):E837–44. doi: https://doi. org/10.1111/j.1464-410x.2012.11288.x

  61. Silva J, Pinto R, Carvalho T, Botelho F, Silva P, Silva C, et al. Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function: SEXUAL EFFECTS AND INTRAPROSTATIC SOLUTIONS TOXIN TYPE A. BJU International. 2011 Jun;107(12):1950– 4. doi: https://doi.org/10.1111/j.1464410x.2010.09841.x




2020     |     www.medigraphic.com